All In MedTech

Device Trial Radar · NCT07308847

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Prospective, Single Arm, Unblinded Pre-market Clinical Study to Evaluate the Safety and Effectiveness of the Sphere-360 Catheter and Affera Mapping and Ablation System for Treating Paroxysmal Atrial Fibrillation (PAF)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

300

Actual

Start

Jan 15, 2026

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Medtronic Cardiac Ablation SolutionsPublic (MDT)
Sponsor type
Industry
First posted
Dec 30, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a prospective, single-arm, pre-market clinical study and will enroll up to 300 subjects at up to 26 sites in the United States (US) for analysis of primary objectives. No single site may contribute more than 15% of the enrollments.

Conditions

  • Paroxysmal AF

Interventions

  • Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation SystemDevice

    Pulmonary Vein Isolation using the Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from Atrial Tachyarrhythmia Recurrence Through 12 Months Post-AblationTime frame: Index ablation procedure through 12 months of follow up.
  2. Incidence of Device- and Procedure-Related Serious Adverse Events Through 6 MonthsTime frame: Index ablation procedure through 6 months of follow up.

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Arrhythmia Research Group

    Jonesboro, Arkansas

  • Scripps Memorial Hospital

    La Jolla, California

  • Mercy General Hospital

    Sacramento, California

21 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.